Key result
WATCHMAN in NVAF allows ~95% of patients to maintain single antiplatelet therapy at one year.
Why the study?
Anticoagulants used for stroke prevention in atrial fibrillation can cause bleeding, making the WATCHMAN device an alternative; this study aimed to describe patient, procedural, and follow-up characteristics in patients undergoing WATCHMAN implantation.
Observational (n=41)
No
WATCHMAN implantation in patients with nonvalvular AF and bleeding history was associated with successful LAA closure and high rates of transition to single antiplatelet therapy at 1 year.
Should not yet change practice in high-bleeding-risk AF; hypothesis-generating for single-antiplatelet transition after WATCHMAN and requires RCTs.
BACKGROUND: Persons with atrial fibrillation (AF) are at risk for stroke. Atrial fibrillation-related strokes most often result for emboli arising from the left atrial appendage (LAA). Stroke prevention includes the use of anticoagulants and/or antiplatelets. These medications can result in bleeding complications. An alternative to anticoagulants is the WATCHMAN device, which is delivered in the left atria resulting in closure of LAA. OBJECTIVE: The aim of this study was to describe patient, procedural, and follow-up characteristics in patients who have undergone WATCHMAN implantation. METHODS: This study used a retrospective design to review data previously collected and entered into the National Cardiovascular Data Registry database. RESULTS: During a 2-year period, 41 patients underwent the WATCHMAN procedure at our facility. The most common indication for the procedure in this population of patients with nonvalvular AF on oral anticoagulants was bleeding in the gastrointestinal or genitourinary systems. (Gastrointestinal/genitourinary bleed does not limit candidacy for surgical closure of the LAA.) There was only 1 postprocedure adverse event that included a groin hematoma. A transesophageal echocardiogram at 45 days indicated that the LAA seal showed no leak or flow around the device or a leak less than 5 mm. At 1 year, 95% (n = 36) of patients were only taking a single antiplatelet drug with aspirin. Eight patients were on a single antiplatelet medication at the time of follow-up 2 years after the procedure. DISCUSSION: A skilled team including a designated AF clinical nurse specialist contributed to program success measured by efficient placement of the WATCHMAN device and discontinuation of anticoagulation.
No takes yet. Share an insight, caveat, or question.
Fowler et al. (2021) conducted an observational in Nonvalvular atrial fibrillation (n=41). WATCHMAN implantation was evaluated on Patient, procedural, and follow-up characteristics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: